https://charts.traderzeitung.de/phases/US35168W1036 string(1399) "{"isin":"US35168W1036","name":"Fractyl Health Inc","stock_id_xnas":39599769,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.578,"close_at":"2026-09-21 21:50:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.553,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-4.3253},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.475,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-14.1049},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Fractyl Health Aktie News & Nachrichten

[WKN: A3EKLV | Symbol: GUTS]

Realtimekurs

Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Fractyl Health gefunden werden.

Fractyl Health Nachrichtenticker öffnen

MT Newswires 01.07.2026 13:51 Uhr

Craig-Hallum nimmt die Coverage für Fractyl Health mit 'Kaufen' und einem Kursziel von $4 auf

07:50 AM EDT, 07/01/2026 (MT Newswires) -- Fractyl Health (GUTS) hat eine durchschnittliche Bewertung von 'Kaufen' und ein mittleres Kursziel von $5,2

MT Newswires 04.06.2026 14:15 Uhr

Fractyl Health: Einjahresdaten zeigen, dass Revita den Gewichtsverlust nach GLP-1 aufrechterhält

08:14 AM EDT, 06/04/2026 (MT Newswires) -- Fractyl Health (GUTS) sagte am Donnerstag, dass Einjahresdaten aus einer offenen Studie zeigten, dass ihr R